MedTrace Logo

A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT00703391 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2012-01-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the tolerability (effect of drug on body) and pharmacokinetics (effect of body on drug) of AZD9668 in patients with mild to moderate COPD

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

AZD9668

30mg oral tablets twice daily (bid) for 14 days

DRUG

Placebo

Matched placebo to 30mg oral tablet twice daily (bid) for 14 days

Sponsors & Collaborators

Principal Investigators

  • Kristina Panke · Parexel International GmbhH (CRO)

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00703391 on ClinicalTrials.gov